Category: Pharmaceuticals
-
![Bioasis Technologies (BTI.V) and The Lind Partners come to financing deal]()
Bioasis Technologies (BTI.V) and The Lind Partners come to financing deal
Bioasis Technologies (BTI.V) entered into a convertible security financing earlier this week with New-York based investment management firm, Lind Global Macro Fund, a subsidiary of The Lind Partners, according to a press release. The terms of the agreement give Bioasis the ability to issue convertible securities up to $10 million with proceeds going to general…
-
![Bioasis Technologies (BTI.V) and the painful price of private sector science]()
Bioasis Technologies (BTI.V) and the painful price of private sector science
Science isn’t cheap. Overhead for scientific based companies is usually sky high for a reason. It’s not just keeping the lights on, or making sure everyone from the CEO to the janitorial staff get paid on time, although that’s part of it. It’s revolving costs in equipment, other forms of capital—like human capital—the average science…
-
![Bioasis Technologies (TXSV:BTI | OTCQB:BIOAF): biopharma dark horse in the making]()
Bioasis Technologies (TXSV:BTI | OTCQB:BIOAF): biopharma dark horse in the making
The New York Times went viral (shocker) in 2015 with their article covering psychologist Arthur Aron’s study on 36 questions that lead to love. #6 is the following: “If you were able to live to the age of 90 and retain either the mind or body of a 30-year-old for the last 60 years of…
-
![Aequus Pharma (AQS.V) update including Q1,2021 financial highlights]()
Aequus Pharma (AQS.V) update including Q1,2021 financial highlights
On May 31, 2021 Aequus Pharmaceuticals (AQS.V) reported financial results for Q1, 2021. Aequus is a $19 million pharmaceutical company focused on developing and commercializing high quality, differentiated products. AQS is building a Canadian commercial platform through its own development pipeline and through license-acquisition. On November 20, 2020 Equity Guru’s Chris Parry spoke with Aequus’…
-
![Valeo’s (VPH.C) Novartis (NVS) Deal Impresses Paradigm Capital Analysts]()
Valeo’s (VPH.C) Novartis (NVS) Deal Impresses Paradigm Capital Analysts
Anyone else watching charts trend downwards? Yeah. There’s a reason that junior market traders hold tight to the saying of “May: sell and go away”, but ‘May’ started unusually early this year. The biggest catalyst of course being the social upheaval that comes with different economies being at different stages of vaccination – and therefore…
-
Revive Therapeutics (RVV.C) files for FDA Orphan Drug Designation for psilocybin in traumatic brain injury
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function after TBI lessening disability”.
-
Parry Special: Short report on Mountain Valley MD Holdings (MVMD.C) earns nothing but rage
When a ‘devastating’ expose on a company opens with the line ‘We are short this company’, I have to say, I find it hard to read much further. To open the discussion admitting you’ll make more money if the company you’re writing about gets obliterated, and then proceed to map out your obliteration strategy, well…
-
![As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat]()
As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat
News this week that Canntab Therapeutics (PILL.C) received an Australian patent for their hard-pressed cannabis pill tech, to match those received earlier in North America, didn’t launch the stock into space. That’s understandable, to be honest, as North American investors have taken an eye off the island continent and its slow roll to weed legalization…
-
![Heritage Cannabis (CANN.C) Receives Health Canada Export License]()
Heritage Cannabis (CANN.C) Receives Health Canada Export License
Heritage Cannabis (CANN.C) has been granted an export license by Health Canada. The license will permit the Company to export cannabis products to Brazil marking the first-ever license granting the export of CBD products from Canada to Brazil. “We are very pleased to be the first cannabis company in Canada to be granted an export…
-
![Aequus Pharma (AQS.V) launches Evolve Eyedrops to eye care professionals in Canada]()
Aequus Pharma (AQS.V) launches Evolve Eyedrops to eye care professionals in Canada
Aequus is a $24 million pharmaceutical company focused on developing and commercializing high quality, differentiated products.
